Probiotic mediated NF-κB regulation for prospective management of type 2 diabetes

Diabetes and other lifestyle disorders have been recognized as the leading cause of morbidity and mortality globally. Nuclear factor kappa B (NF-kappa B) is a major factor involved in the early pathobiology of diabetes and studies reveal that hyperglycemic conditions in body leads to NF-kappa B mediated activation of several cytokines, chemokines and inflammatory molecules. NF-kappa B family comprises of certain DNA-binding protein factors that elicit the transcription of pro-inflammatory molecules. Various studies have identified NF-kappa B as a promising target for diabetic management. Probiotics have been proposed as bio-therapeutic agents for treatment of inflammatory disorders and many other chronic clinical stages. The precise mechanisms by which probiotics acts is yet to be fully understood, however research findings have indicated their role in NF-kappa B modulation. The current review highlights NF-kappa B as a bio-therapeutic target for probable management of type 2 diabetes through probiotic intervention.